[
  {
    "ts": "2025-10-27T20:05:00+00:00",
    "headline": "Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis",
    "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).",
    "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-approved-200500609.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "b6212cd1-312d-3f0a-836b-aea703e79e19",
      "content": {
        "id": "b6212cd1-312d-3f0a-836b-aea703e79e19",
        "contentType": "STORY",
        "title": "Lilly's Omvoh (mirikizumab-mrkz) approved by U.S. FDA as a single-injection maintenance regimen in adults with ulcerative colitis",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to severely active ulcerative colitis (UC).",
        "pubDate": "2025-10-27T20:05:00Z",
        "displayTime": "2025-10-27T20:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-approved-200500609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-approved-200500609.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T18:00:00+00:00",
    "headline": "Lilly declares fourth-quarter 2025 dividend",
    "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.",
    "url": "https://finance.yahoo.com/news/lilly-declares-fourth-quarter-2025-180000070.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "47d7102c-6177-3d4c-8360-0eac08e9909b",
      "content": {
        "id": "47d7102c-6177-3d4c-8360-0eac08e9909b",
        "contentType": "STORY",
        "title": "Lilly declares fourth-quarter 2025 dividend",
        "description": "",
        "summary": "The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock.",
        "pubDate": "2025-10-27T18:00:00Z",
        "displayTime": "2025-10-27T18:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-declares-fourth-quarter-2025-180000070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-declares-fourth-quarter-2025-180000070.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T17:00:00+00:00",
    "headline": "Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced a new partnership with NBA Hall of Famer and cultural icon Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). The initiative aims to educate the public about the symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity.",
    "url": "https://finance.yahoo.com/news/lilly-drafts-shaquille-oneal-raise-170000226.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "79b8335d-b4ba-3b67-95b7-b825327f86db",
      "content": {
        "id": "79b8335d-b4ba-3b67-95b7-b825327f86db",
        "contentType": "STORY",
        "title": "Lilly Drafts Shaquille O'Neal to Raise Awareness for Moderate-to-Severe Obstructive Sleep Apnea",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced a new partnership with NBA Hall of Famer and cultural icon Shaquille O'Neal to launch a nationwide campaign raising awareness about moderate-to-severe obstructive sleep apnea (OSA). The initiative aims to educate the public about the symptoms and potential health impacts of moderate-to-severe OSA, a serious but often overlooked health condition that impacts 24 million people in the U.S., many of whom are overweight or living with obesity.",
        "pubDate": "2025-10-27T17:00:00Z",
        "displayTime": "2025-10-27T17:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-drafts-shaquille-oneal-raise-170000226.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-drafts-shaquille-oneal-raise-170000226.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T16:21:22+00:00",
    "headline": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
    "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
    "url": "https://www.fool.com/investing/2025/10/27/what-is-1-of-best-pharmaceutical-stocks-buy-now/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "157e9131-4e89-3318-a389-106146a84e79",
      "content": {
        "id": "157e9131-4e89-3318-a389-106146a84e79",
        "contentType": "STORY",
        "title": "What Is 1 of the Best Pharmaceutical Stocks to Buy Now?",
        "description": "",
        "summary": "This pharma giant is entering the rapidly expanding market for weight loss drugs.",
        "pubDate": "2025-10-27T16:21:22Z",
        "displayTime": "2025-10-27T16:21:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5dee2622df65f71d9c939f098cf27be9",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Healthcare lab technicians doing research.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/P_n2gqHYH2n7t8Hk5uAkJg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5dee2622df65f71d9c939f098cf27be9.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/D0mBNVjiBKsYc4i9lC.C1g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5dee2622df65f71d9c939f098cf27be9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/27/what-is-1-of-best-pharmaceutical-stocks-buy-now/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/1-best-pharmaceutical-stocks-buy-162122563.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T15:54:37+00:00",
    "headline": "Jim Cramer on Eli Lilly: “It’s Become Luckless”",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated: “How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-become-155437415.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "02b5cf45-b120-3cdb-86d0-f12d42ced28d",
      "content": {
        "id": "02b5cf45-b120-3cdb-86d0-f12d42ced28d",
        "contentType": "STORY",
        "title": "Jim Cramer on Eli Lilly: “It’s Become Luckless”",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE:LLY) is one of the stocks in focus in the game plan Jim Cramer shared. Cramer noted that the company needs to find a new use for its GLP-1 drug, as he stated: “How about Eli Lilly? Now, I hate to say it, but it’s become luckless. If the company doesn’t […]",
        "pubDate": "2025-10-27T15:54:37Z",
        "displayTime": "2025-10-27T15:54:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5",
          "originalWidth": 700,
          "originalHeight": 500,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Wyy4UWrSKL87q_fyeH45LA--~B/aD01MDA7dz03MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 700,
              "height": 500,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AnFYVFBsFAzROcOJguXtPQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/4297bceadd7b3662bc208031885247f5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-become-155437415.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-eli-lilly-become-155437415.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T15:05:00+00:00",
    "headline": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
    "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
    "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-150500468.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "60f5b247-077e-35b7-b87f-3723bea398fb",
      "content": {
        "id": "60f5b247-077e-35b7-b87f-3723bea398fb",
        "contentType": "STORY",
        "title": "What's in Store for These 5 Pharma Bigwigs This Earnings Season?",
        "description": "",
        "summary": "As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.",
        "pubDate": "2025-10-27T15:05:00Z",
        "displayTime": "2025-10-27T15:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-150500468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whats-store-5-pharma-bigwigs-150500468.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CELG-RT"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ROG.SW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T15:00:00+00:00",
    "headline": "Down 15%, Should You Buy the Dip on Eli Lilly?",
    "summary": "Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.",
    "url": "https://www.fool.com/investing/2025/10/27/down-15-should-you-buy-the-dip-on-eli-lilly/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "1b58e6e7-62b0-3e1b-982d-aab257b0a555",
      "content": {
        "id": "1b58e6e7-62b0-3e1b-982d-aab257b0a555",
        "contentType": "STORY",
        "title": "Down 15%, Should You Buy the Dip on Eli Lilly?",
        "description": "",
        "summary": "Lilly's stock has pulled back from its 2024 highs, but that doesn't mean the shares are cheap enough to buy.",
        "pubDate": "2025-10-27T15:00:00Z",
        "displayTime": "2025-10-27T15:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/19fee6a950267311bff4649069d24ab0",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A person using an injection pen.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T7njIA9yYcgLb1gEF6xz6Q--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/19fee6a950267311bff4649069d24ab0.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WeJyew3po2Rw2lXb94seaQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/19fee6a950267311bff4649069d24ab0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/27/down-15-should-you-buy-the-dip-on-eli-lilly/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/down-15-buy-dip-eli-150000894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T13:52:00+00:00",
    "headline": "Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings",
    "summary": "Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.",
    "url": "https://finance.yahoo.com/news/buy-sell-hold-lilly-stock-135200440.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "692549be-914b-3738-9fd1-f29b5fbd7e32",
      "content": {
        "id": "692549be-914b-3738-9fd1-f29b5fbd7e32",
        "contentType": "STORY",
        "title": "Buy, Sell or Hold Lilly Stock? Key Tips Ahead of Q3 Earnings",
        "description": "",
        "summary": "Eli Lilly's Q3 results hinge on strong demand for Mounjaro and Zepbound as investors weigh growth drivers against the pressure of pricing and competition.",
        "pubDate": "2025-10-27T13:52:00Z",
        "displayTime": "2025-10-27T13:52:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MjuR.4zEKm0FgKsxK.lBKQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G.VCDKzJSEg_sv.1sSAJrQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/buy-sell-hold-lilly-stock-135200440.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-sell-hold-lilly-stock-135200440.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T13:15:02+00:00",
    "headline": "Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics",
    "summary": "Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
    "url": "https://finance.yahoo.com/news/seeking-clues-lilly-lly-q3-131502933.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "83c797f6-6745-33ff-8017-cf48fdb5e26c",
      "content": {
        "id": "83c797f6-6745-33ff-8017-cf48fdb5e26c",
        "contentType": "STORY",
        "title": "Seeking Clues to Lilly (LLY) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics",
        "description": "",
        "summary": "Besides Wall Street's top-and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.",
        "pubDate": "2025-10-27T13:15:02Z",
        "displayTime": "2025-10-27T13:15:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f",
          "originalWidth": 900,
          "originalHeight": 601,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EmhBrL1RMEs5kGBSUQzx5g--~B/aD02MDE7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 900,
              "height": 601,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CMWRvhn58nUVOwpQjtvr2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/bdc2850a48a0f40806db817a9e24f36f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/seeking-clues-lilly-lly-q3-131502933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/seeking-clues-lilly-lly-q3-131502933.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T12:16:22+00:00",
    "headline": "Eli Lilly buys Adverum in eye disease gene therapy punt",
    "summary": "For Adverum, the potential buyout from Eli Lilly provides financial respite.",
    "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-buys-adverum-in-eye-disease-gene-therapy-punt/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "52ceab43-813b-3be2-96b5-dc43401a6c39",
      "content": {
        "id": "52ceab43-813b-3be2-96b5-dc43401a6c39",
        "contentType": "STORY",
        "title": "Eli Lilly buys Adverum in eye disease gene therapy punt",
        "description": "",
        "summary": "For Adverum, the potential buyout from Eli Lilly provides financial respite.",
        "pubDate": "2025-10-27T12:16:22Z",
        "displayTime": "2025-10-27T12:16:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/16c6dc6605f232ecc19c60287daf8ebc",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1h9wayhpXYtJDXvQLvGCeA--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/16c6dc6605f232ecc19c60287daf8ebc.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JOga8KiRrleizR7ZQXW1aQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/16c6dc6605f232ecc19c60287daf8ebc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/eli-lilly-buys-adverum-in-eye-disease-gene-therapy-punt/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-buys-adverum-eye-121622936.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ADVM"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T11:31:00+00:00",
    "headline": "Should You Buy Eli Lilly Stock Before Oct. 30?",
    "summary": "Long-term investors don't need to rush to buy Eli Lilly stock.",
    "url": "https://www.fool.com/investing/2025/10/27/should-you-buy-eli-lilly-stock-before-october-30th/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "15a7b5f1-62df-31d6-866b-d6171e79c74c",
      "content": {
        "id": "15a7b5f1-62df-31d6-866b-d6171e79c74c",
        "contentType": "STORY",
        "title": "Should You Buy Eli Lilly Stock Before Oct. 30?",
        "description": "",
        "summary": "Long-term investors don't need to rush to buy Eli Lilly stock.",
        "pubDate": "2025-10-27T11:31:00Z",
        "displayTime": "2025-10-27T11:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/5eb59ce852cfcbb6db8d8e578b554461",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Scientists in white lab coats.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IM5WIS.6kfxedyLIMxLLTg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5eb59ce852cfcbb6db8d8e578b554461.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/q4S.WgydydfsNNIHgDl.oQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/5eb59ce852cfcbb6db8d8e578b554461.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/27/should-you-buy-eli-lilly-stock-before-october-30th/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/buy-eli-lilly-stock-oct-113100136.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T10:45:00+00:00",
    "headline": "Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis",
    "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks. The Phase 3b single-arm, open-label LUCENT-URGE study was specifically designed to assess bowel urgency and is the first in inflammatory bowel disease to include the novel endpoints of bo",
    "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-demonstrated-104500781.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "69fec881-04ca-3240-91a3-c2de91ba8822",
      "content": {
        "id": "69fec881-04ca-3240-91a3-c2de91ba8822",
        "contentType": "STORY",
        "title": "Lilly's Omvoh (mirikizumab-mrkz) demonstrated early and sustained improvement in bowel urgency outcomes for patients with ulcerative colitis",
        "description": "",
        "summary": "New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh-treated patients with moderately to severely active ulcerative colitis (UC) and bowel urgency experienced early improvements in bowel urgency severity, frequency and stool deferral time by Week 12. These outcomes continued to improve through 28 weeks. The Phase 3b single-arm, open-label LUCENT-URGE study was specifically designed to assess bowel urgency and is the first in inflammatory bowel disease to include the novel endpoints of bo",
        "pubDate": "2025-10-27T10:45:00Z",
        "displayTime": "2025-10-27T10:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-demonstrated-104500781.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-omvoh-mirikizumab-mrkz-demonstrated-104500781.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T10:30:00+00:00",
    "headline": "Hedge Fund Assets Reach Record $5 Trillion With Most Inflows Since 2007",
    "summary": "The last time this many people piled into hedge funds, the only great recession anyone might have been aware of was Larry David’s hairline.",
    "url": "https://www.thedailyupside.com/finance/hedge-funds/hedge-funds-hit-record-5-trillion-in-assets-under-management-and-see-most-inflows-since-2007/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "6f1e0be3-483e-3371-bc83-220566fabaeb",
      "content": {
        "id": "6f1e0be3-483e-3371-bc83-220566fabaeb",
        "contentType": "STORY",
        "title": "Hedge Fund Assets Reach Record $5 Trillion With Most Inflows Since 2007",
        "description": "",
        "summary": "The last time this many people piled into hedge funds, the only great recession anyone might have been aware of was Larry David’s hairline.",
        "pubDate": "2025-10-27T10:30:00Z",
        "displayTime": "2025-10-27T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/234b3325eb6dc706aca92e284b557a9b",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of a Wall Street sign.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JpjtEUUmAyhlvV1p.pX_Xw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/234b3325eb6dc706aca92e284b557a9b.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BkdlGkDIsWJ4EfgmjjfgfA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/234b3325eb6dc706aca92e284b557a9b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/finance/hedge-funds/hedge-funds-hit-record-5-trillion-in-assets-under-management-and-see-most-inflows-since-2007/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/hedge-fund-assets-reach-record-103000711.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T10:30:00+00:00",
    "headline": "Can Beyond Meat’s Meme-Stock Star Turn Last Beyond Last Week?",
    "summary": "Beyond reported a 20% year-over-year revenue decline in its latest quarter, so this was not a fundamentals-driven rally.",
    "url": "https://www.thedailyupside.com/finance/beyond-meats-meme-stock-star-turn-unlikely-to-go-beyond-last-week/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "715aed86-b96f-3a0d-8184-a548aa9fc4df",
      "content": {
        "id": "715aed86-b96f-3a0d-8184-a548aa9fc4df",
        "contentType": "STORY",
        "title": "Can Beyond Meat’s Meme-Stock Star Turn Last Beyond Last Week?",
        "description": "",
        "summary": "Beyond reported a 20% year-over-year revenue decline in its latest quarter, so this was not a fundamentals-driven rally.",
        "pubDate": "2025-10-27T10:30:00Z",
        "displayTime": "2025-10-27T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/80887159b0a31af1b4e3ae8d5211d605",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "Photo of Beyond Meat's \"beef\" product at a supermarket.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/iYp7YDlRzufC30fuvKr8QA--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/80887159b0a31af1b4e3ae8d5211d605.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mcZAf_vXPQOmIhy4gEuxwg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/80887159b0a31af1b4e3ae8d5211d605.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/finance/beyond-meats-meme-stock-star-turn-unlikely-to-go-beyond-last-week/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/beyond-meat-meme-stock-star-103000542.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BYND"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T10:10:00+00:00",
    "headline": "Goldman’s New Fund Designed for PE Returns, Sans the PE",
    "summary": "The Goldman Sachs MSCI World Private Equity Return Tracker ETF does its best to replicate PE performance with publicly traded stocks.",
    "url": "https://www.thedailyupside.com/etf/investing-strategies-etf/goldmans-new-fund-designed-for-pe-returns-sans-the-pe/",
    "source": "The Daily Upside",
    "provider": "yfinance",
    "raw": {
      "id": "f896da28-8196-346c-8839-1aa763e05a97",
      "content": {
        "id": "f896da28-8196-346c-8839-1aa763e05a97",
        "contentType": "STORY",
        "title": "Goldman’s New Fund Designed for PE Returns, Sans the PE",
        "description": "",
        "summary": "The Goldman Sachs MSCI World Private Equity Return Tracker ETF does its best to replicate PE performance with publicly traded stocks.",
        "pubDate": "2025-10-27T10:10:00Z",
        "displayTime": "2025-10-27T10:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/the_daily_upside_435/aacccd15b10aeaedf6eb16c7a150060a",
          "originalWidth": 1600,
          "originalHeight": 901,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OtbuMPJBq6tE3eini5iEnw--~B/aD05MDE7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_daily_upside_435/aacccd15b10aeaedf6eb16c7a150060a.cf.webp",
              "width": 1600,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ruk.65mS5PnOuOgeJ2GT3A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/the_daily_upside_435/aacccd15b10aeaedf6eb16c7a150060a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Daily Upside",
          "url": "http://thedailyupside.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thedailyupside.com/etf/investing-strategies-etf/goldmans-new-fund-designed-for-pe-returns-sans-the-pe/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/goldman-fund-designed-pe-returns-101000034.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GS"
            },
            {
              "symbol": "GTPE"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PLTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-27T08:31:48+00:00",
    "headline": "Novartis to Acquire Avidity Biosciences for $72 per Share",
    "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
    "url": "https://finance.yahoo.com/news/novartis-acquire-avidity-biosciences-72-083148199.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "c7796aae-6890-37f4-bdc9-4f2093e0d551",
      "content": {
        "id": "c7796aae-6890-37f4-bdc9-4f2093e0d551",
        "contentType": "STORY",
        "title": "Novartis to Acquire Avidity Biosciences for $72 per Share",
        "description": "",
        "summary": "Avidity Biosciences (RNA) has agreed to be acquired by Novartis (NVS) for $72 per share in a deal th",
        "pubDate": "2025-10-27T08:31:48Z",
        "displayTime": "2025-10-27T08:31:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novartis-acquire-avidity-biosciences-72-083148199.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novartis-acquire-avidity-biosciences-72-083148199.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "RNA"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]